Evidence map›Paper›PMID 33649343›Full record

ArticleNPJ Parkinson's disease2021

The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism.

Caroline M Tanner, Steven R Cummings, Michael A Schwarzschild, Ethan G Brown, E Ray Dorsey, Alberto J Espay, Nicholas B Galifianakis, Samuel M Goldman, Irene Litvan, Nijee Luthra and 7 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03924414 (TOPAZ), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03924414 phase4completednot on this map

TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease

TypeinterventionalSponsorCalifornia Pacific Medical Center Research InstituteRan2019 to 2026Enrolled2,721ConditionsParkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and ParkinsonismArmsZoledronic Acid 5Mg/Bag 100Ml Inj, Placebo
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Reconsidering fracture risk reduction in Parkinson's disease: limitations of claims-based inference.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Inclusion of Non-English-Speaking Participants in Studies of Parkinson's Disease: A Call to Action.Movement disorders : official journal of the Movement Disorder Society · 2022
    Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 1 country.

Caroline M TannerDepartment of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA. caroline.tanner@ucsf.edu.ORCID http://orcid.org/0000-0002-3775-5082
Steven R CummingsSan Francisco Coordinating Center,California Pacific Medical Center Research Institute, Departments of Medicine and Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Michael A SchwarzschildMassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Ethan G BrownDepartment of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9744-8562
E Ray DorseyCenter for Health + Technology and Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.
Alberto J EspayJames J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA.
Nicholas B GalifianakisDepartment of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Samuel M GoldmanDepartment of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Irene LitvanParkinson and Other Movement Disorders Center, Department of Neuroscience, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-3485-3445
Nijee LuthraDepartment of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Nikolaus R McFarlandNorman Fixel Institute for Neurological Diseases, Department of Neurology, University of Florida College of Medicine, Gainesville, FL, USA.
Kyle T MitchellDepartment of Neurology, Duke University School of Medicine, Durham, NC, USA.
David G StandaertDepartment of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0003-2921-8348
Douglas C BauerDepartments of Medicine and Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Susan L GreenspanOsteoporosis Prevention and Treatment Center, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
James C BeckParkinson's Foundation, New York, NY, USA.ORCID http://orcid.org/0000-0002-4884-9893
Kenneth W LylesDepartment of Medicine, Duke University School of Medicine, VA Medical Center, Durham, NC, USA.
University of California, San Francisco · USDuke Medical Center · USDuke University · USMassachusetts General Hospital · USParkinson's Foundation · USUniversity of Alabama at Birmingham · USUniversity of California San Diego · USUniversity of Cincinnati · USUniversity of Florida · USUniversity of Pittsburgh · USUniversity of Rochester Medical Center · US

Funding

Prevention of Fractures in Patients with Parkinson's DiseaseR01AG059417 · NIA · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI CUMMINGS, STEVEN RON, TANNER, CAROLINE M. · 2018 to 2024
$32.6M
VARIABILITY, STABILITY & SMOOTHNESS OF WALKINGP30AG024827 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Caterina Rosano · 2004 to 2026
$28.6M
NIA NIH HHS P30 AG024827NIA NIH HHS R01 AG059417U.S. Department of Health & Human Services | National Institutes of Health (NIH) 1R01AG059417-01A1
6 · The paper itself

Abstract

The Trial of Parkinson's And Zoledronic acid (TOPAZ, https://clinicaltrials.gov/ct2/show/NCT03924414 ) is a unique collaboration between experts in movement disorders and osteoporosis to test the efficacy of zoledronic acid, an FDA-approved parenteral treatment for osteoporosis, for fracture prevention in people with neurodegenerative parkinsonism. Aiming to enroll 3,500 participants age 65 years or older, TOPAZ is one of the largest randomized, placebo-controlled clinical trials ever attempted in parkinsonism. The feasibility of TOPAZ is enhanced by its design as a U.S.- wide home-based trial without geographical limits. Participants receive information from multiple sources, including specialty practices, support groups and websites. Conducting TOPAZ in participants' homes takes advantage of online consent technology, the capacity to confirm diagnosis using telemedicine and the availability of research nursing to provide screening and parenteral therapy in homes. Home-based clinical research may provide an efficient, convenient, less expensive method that opens participation in clinical trials to almost anyone with parkinsonism.

Identifiers

PMID33649343
PMCPMC7921548
OpenAlexW3135855865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.